Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance 
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
WAYNE, Pa., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
Compass Therapeutics to Participate in Upcoming December Investor Events
BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...
CytomX Therapeutics to Present at Upcoming December Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
Mike Tyson and TerrAscend Team Up To Launch Tyson 2.0 In Maryland And Pennsylvania
TORONTO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North...
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage...
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
Event scheduled for Tuesday, December 2nd at 8:00 AM ETFort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma,...
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
NAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or...
Historic Win for Electrophysiology Reimbursement in Ambulatory Surgery Centers Provides Unique Opportunity for Catheter Precision’s LockeT Device
FORT MILL, S.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device...
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer...
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a...
Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer
Continued Integration of ezBVA Lab Service and On-Site Analyzer Deployment Signals Accelerating Market Traction Oak Ridge, TN, Nov. 25, 2025...
PetVivo Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-89%
Revolutionary PetVivo.ai Uses Nine AI Agents to Transform $150B Pet Care Market MINNEAPOLIS, Nov. 25, 2025 (GLOBE NEWSWIRE) -- PetVivo...
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full...
Flare Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to...
BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025
BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025
Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and...
BridgeBio to Participate in December Investor Conferences
PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new...
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from...
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Anavex...
Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial
First patient recruited at leading Israeli site accelerating enrollment momentum across global study of CMND-100 Vancouver, Canada, Nov. 25, 2025...